These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 2654791

  • 1. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
    Linkesch W, Michlmayr G, Gerhartz H, Illinger H, König H, Düllmann J, Keilhauer R, Moldrzyk D.
    Onkologie; 1989 Feb; 12(1):8-10. PubMed ID: 2654791
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR, Weiner RS, Moore JO, Omura GA, Bartolucci AA, Stagg M.
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [Abstract] [Full Text] [Related]

  • 4. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
    Archimbaud E, Fiere D, Treille-Ritouet D, Adeleine P, Guyotat D, Sebban C, Vuvan H, Viala JJ.
    Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
    [Abstract] [Full Text] [Related]

  • 5. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A, German AML Cooperative Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4496-504. PubMed ID: 14673036
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
    Stein RS, Vogler WR, Winton EF, Cohen HJ, Raney MR, Bartolucci A.
    Leuk Res; 1990 Dec 15; 14(10):895-903. PubMed ID: 2259226
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB.
    Leukemia; 1991 Jun 15; 5(6):510-6. PubMed ID: 2056774
    [Abstract] [Full Text] [Related]

  • 12. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
    Büchner T, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G.
    J Clin Oncol; 1985 Dec 15; 3(12):1583-9. PubMed ID: 3906048
    [Abstract] [Full Text] [Related]

  • 13. Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
    Marcus RE, Catovsky D, Prentice HG, Newland AC, Chessells JM, Stevens RF, Hann IM, Goldman JM, Hoffbrand AV, Galton DA.
    Haematol Blood Transfus; 1987 Dec 15; 30():346-51. PubMed ID: 2442074
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Daunomycin, cytosine arabinoside and 6-thioguanine (DAT) vs vincristine, cytosine arabinoside and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocyte leukemia: a randomized collaborative study.
    Mandelli F, De Lipsis E, Grignani F, Martelli M, Liso V, Amadori S.
    Med Pediatr Oncol; 1978 Dec 15; 4(3):231-40. PubMed ID: 277749
    [Abstract] [Full Text] [Related]

  • 16. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial.
    Rees JK, Gray RG, Swirsky D, Hayhoe FG.
    Lancet; 1986 Nov 29; 2(8518):1236-41. PubMed ID: 2878130
    [Abstract] [Full Text] [Related]

  • 17. Varying intensity of postremission therapy in acute myeloid leukemia.
    Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, McGlave PB, Edelstein M, Harrington DP, O'Connell MJ.
    Blood; 1992 Apr 15; 79(8):1924-30. PubMed ID: 1562720
    [Abstract] [Full Text] [Related]

  • 18. Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukemia: MRC ninth AML trial.
    Rees JK, Gray R.
    Semin Oncol; 1987 Jun 15; 14(2 Suppl 1):32-6. PubMed ID: 3473681
    [Abstract] [Full Text] [Related]

  • 19. Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis.
    Kessler T, Mohr M, Müller-Tidow C, Krug U, Brunnberg U, Mohr B, Schliemann C, Sauerland C, Serve H, Büchner T, Berdel WE, Mesters RM.
    Leuk Res; 2008 Mar 15; 32(3):491-4. PubMed ID: 17675230
    [Abstract] [Full Text] [Related]

  • 20. A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study.
    Steuber CP, Civin C, Krischer J, Culbert S, Ragab A, Ruymann FB, Ravindranath Y, Leventhal B, Wilkinson R, Vietti TJ.
    J Clin Oncol; 1991 Feb 15; 9(2):247-58. PubMed ID: 1988573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.